IRLAB Therapeutics AB (IRLABa)

Stockholm

Currency in SEK

12.600

+0.100(+0.80%)

Closed11:30:59

Fair Value

Day's Range

12.400

12.600

52 wk Range

5.580

20.200

IRLABa Income Statement

Featured here, the Income Statement (earnings report) for IRLAB Therapeutics AB, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Advanced Income Statement

Period Ending:

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

Total Revenues

0.37

0.3

207.78

61.14

5.68

Total Revenues Growth

+89.8%

-19.35%

+69,160.67%

-70.58%

-90.71%

Cost Of Revenues

71.16

65.63

81.74

125.91

128.41

Gross Profit

-70.79

-65.33

126.05

-64.77

-122.73

Gross Profit Growth

-30.91%

+7.71%

+292.94%

-151.39%

-89.49%

Gross Profit Margin %

-19,029.57%

-21,776.67%

60.66%

-105.94%

-2,161.57%

Other Operating Expenses, Total

24.39

26.23

73.47

47.23

57.36

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+27.82%	+7.54%	+180.07%	-35.71%	+21.43%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	22.14	23.97	31.02	42.48	53.08
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	0.07	0.01	38.97	-0.03	-0.04

Operating Income

-95.18

-91.56

52.58

-112

-180.09

Operating Income Growth

-30.11%

+3.8%

+157.42%

-313.03%

-60.79%

EBIT Margin %

-25,586.56%

-30,520.67%

25.3%

-183.2%

-3,171.72%

Net Interest Expenses

-0.27

-0.19

-0.37

-0.3

2.93

Net Interest Expenses Growth

-34.65%

+28.68%

-90.21%

+19.51%

+1,085.19%

Interest Expense, Total

-0.27

-0.2

-0.37

-0.3

-0.2

Interest And Investment Income

-

0

0

-

3.13

Other Non Operating Expenses, Total

-

0.1

-0.43

-1.11

-0.68

EBT, Excl. Unusual Items

-95.45

-91.65

51.78

-113.41

-177.84

Gain (Loss) On Sale Of Assets

-

-

-

-

-

Other Unusual Items, Total

-0.67

-

-

-

-

EBT, Incl. Unusual Items

-96.12

-91.65

51.78

-113.41

-177.84

EBT, Incl. Unusual Items Growth

-29.72%

+4.65%

+156.5%

-319.01%

-56.82%

EBT, Incl. Unusual Items Margin

-25,838.71%

-30,551%

24.92%

-185.5%

-3,132.07%

Income Tax Expense

-

-

-

-

-

Net Income to Company

-96.12

-91.65

51.78

-113.41

-177.84

Minority Interest

-

-

-

-

-

Net Income

-96.12

-91.65

51.78

-113.41

-177.84

Net Income Growth

-29.72%

+4.65%

+156.5%

-319.01%

-56.82%

Net Income Margin %

-25,838.71%

-30,551%

24.92%

-185.5%

-3,132.07%

Preferred Dividend and Other Adjustments

-

-

-

-

-

Net Income to Common Excl. Extra Items

-96.12

-91.65

51.78

-113.41

-177.84

Basic EPS - Continuing Operations

-2.37

-1.92

1

-2.19

-3.43

Basic EPS - Continuing Operations Growth

-22.2%

+18.82%

+152.05%

-318.66%

-56.71%

Diluted EPS - Continuing Operations

-2.37

-1.92

1

-2.19

-3.43

Diluted EPS - Continuing Operations Growth

-22.2%

+18.82%

+152.02%

-318.8%

-56.71%

Basic Weighted Average Shares Outstanding

40.59

47.68

51.75

51.83

51.87

Diluted Weighted Average Shares Outstanding

40.59

47.68

51.75

51.83

51.87

Dividend Per Share

-

-

-

-

-

Dividend Per Share Growth

-

-

-

-

-

EBITDA

-94.91

-91.23

53.07

-111.27

-179.17

EBITDA Growth

-30.33%

+3.88%

+158.17%

-309.66%

-61.03%

EBITDA Margin %

-25,514.25%

-30,409.67%

25.54%

-182%

-3,155.48%

EBIT